U.S. court rules for Eisai in drug fight with Teva
WASHINGTON (Reuters) - Japan's Eisai Co Ltd (4523.T) won a legal fight on Monday with Israel's Teva Pharmaceutical Industries Ltd TEVA.O, the world's largest generic drug company, over acid reflux drug Aciphex.
The U.S. Court of the Appeals for the Federal Circuit upheld a summary judgment by a New York court that found the Eisai patent for Aciphex was valid.
That court also ruled after a bench trial that Teva and Indian drug maker Dr. Reddy's Laboratories Ltd (REDY.BO)(RDY.N) infringed on Eisai's patent based on the fact that each of the two filed an abbreviated new drug application, or ANDA, seeking to manufacture a generic version of Aciphex.
The case also affects Mylan Inc MYL.N, which also filed an ANDA on the drug. Mylan had agreed to be bound by the outcome of Eisai's lawsuit against Teva and Dr. Reddy's.
- Tweet this
- Share this
- Digg this
- UPDATE 7-Tennis-Paris Masters men's singles round 3 results
- Kurds' battle for Kobani unites a people divided by borders
- RBS takes 400 million pound forex hit and warns more to come
- British banks buoyed by new rules on risk buffers
- Japan's central bank shocks markets with more easing as inflation slows |